Purine and deazapurine nucleosides: Synthetic approaches, molecular modelling and biological activity

Farmaco

Volumn 58, Issue 3, 2003, Pages 193-204

  Cristalli, Gloria ^a   Costanzi, Stefano ^a   Lambertucci, Catia ^a   Taffi, Sara ^a   Vittori, Sauro ^a   Volpini, Rosaria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Adenosine receptor ligands; Adenosine receptor molecular modeling; Glycosylation reactions; Nucleoside synthesis

Indexed keywords

2 DEOXYRIBOSE; 2,6 DICHLORO 1 DEAZAPURINE; 2,6 DICHLORO 3 DEAZAPURINE; 2,6 DICHLOROPURINE; 3 DEOXYRIBOSE; ADENOSINE; GUANOSINE; NUCLEOSIDE; PURINE DERIVATIVE; RIBOSE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BINDING; DRUG SYNTHESIS; GLYCOSYLATION; HUMAN; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

EID: 0037373730     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00019-3     Document Type: Article

References (43)

1. G. Cristalli, R. Volpini (ed.), Adenosine Receptors: Medicinal Chemistry, Pharmacology and Therapeutic Applications, Current Topics in Medicinal Chemistry, 3 (2003) 355-469.
2. D. Salvatori, R. Volpini, S. Vincenzetti, A. Vita, S. Costanzi, C. Lambertucci, G. Cristalli, S. Vittori, Adenine and deazaadenine nucleoside and deoxy-nucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1, Bioorg. Med. Chem., 10 (2002) 2973-2980.
3. Cristalli G., Costanzi S., Lambertucci C., Lupidi G., Vittori S., Volpini R., Camaioni E. Adenosine deaminase: functional implication and different classis of inhibitors. Med. Res. Rev. 21:2001;105-128.
4. Cristalli G., Vittori S., Eleuteri A., Grifantini M., Volpini R., Lupidi G., Capolongo L., Pesenti E. Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity. J. Med. Chem. 33:1991;2226-2230.
5. 6-cycloalkyl derivatives of 1-deazapurine nucleosides: a new class of anti-immunodeficiency virus agents. J. Med. Chem. 38:1995;4019-4025.
6. Cristalli G., Camaioni E., Di Francesco E., Eleuteri A., Vittori S., Volpini R. Potent and selective ligand for adenosine binding site. Nucleosides Nucleotides. 16:1997;1379-1388.
7. Volpini R., Camaioni E., Costanzi S., Vittori S., Cristalli G. Synthesis of new 3′-deoxy ribonucleosides employing the acid-catalyzed fusion method. Helv. Chim. Acta. 81:1998;2326-2331.
8. Volpini R., Camaioni E., Costanzi S., Vittori S., Lupidi G., Cristalli G. Synthesis and adenosine deaminase inhibitory activity of 3′-deoxy-1-deazaadenosines. Helv. Chim. Acta. 82:1999;2212-2218.
9. -6-substituted-2′-deoxyadenosines. J. Med. Chem. 43:2000;250-260.
10. Cristalli G., Grifantini M., Vittori S., Balduini W., Cattabeni F. Adenosine and 2-chloroadenosine deaza-analogues as adenosine receptor agonists. Nucleosides Nucleotides. 4:1985;625-639.
11. Cristalli G., Vittori S., Eleuteri A., Volpini R., Cola D., Camaioni E., Gariboldi P.V., Lupidi G. Synthesis of 1,7-dideazapurine ribonucleosides and deoxyribonucleosides. Nucleosides Nucleotides. 12:1993;39-53.
12. S. Vittori, S. Costanzi, C. Lambertucci, S. Taffi, R. Volpini, G. Cristalli, Deaza and deoxy adenosine derivatives: synthesis and inhibition of animal viruses as human infection models, Nucleos Nucleot Nucl (in press).
13. HYPERCHEM 5.02, Hypercube Inc., USA, 1997.
14. Camaioni E., Costanzi S., Vittori S., Volpini R., Klotz K.-N., Cristalli G. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg. Med. Chem. 6:1998;523-533.
15. Cristalli G., Camaioni E., Costanzi S., Vittori S., Volpini R., Klotz K.N. Characterization of potent ligands at human adenosine receptor. Drug Dev. Res. 45:1998;176-181.
16. R. Volpini, S. Costanzi, C. Lambertucci, S. Vittori, G. Cristalli, Purine nuclosides bearing 1-alkynyl chains as adenosine receptor agonists, Curr. Pharm. Des., 8 (2002) 2285-2298.
17. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
18. Horn F., Vriend G., Cohen F.E. Collecting and harvesting biological data: the GPCRDB and NucleaRDB databases. Nucleic Acids Res. 29:2001;346-349.
19. Palmer T.M., Stiles G.L. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol. Pharmacol. 57:2000;539-545.
20. Chen A., Gao Z.G., Barak D., Liang B.T., Jacobson K.A. Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. Biochem. Biophys. Res. Commun. 284:2001;596-601.
21. Jacobson K.A., Gao Z.G., Chen A., Barak D., Kim S.A., Lee K., Link A., Rompaey P.V., van Calenbergh S., Liang B.T. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem. 44:2001;4125-4136.
22. Liang B.T., Jacobson K.A. Adenosine and ischemic preconditioning. Curr. Pharm. Des. 5:1999;1029-1041.
23. 3 receptors during prolonged simulated ischemia. Am. J. Physiol. 273:1997;H501-H505.
24. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. USA. 95:1998;6995-6999.
25. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur. J. Pharmacol. 367:1999;157-163.
26. Jacobson K.A., Von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-113.
27. 2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J. Med. Chem. 37:1994;1720-1726.
28. 2a adenosine receptor agonists. J. Med. Chem. 38:1995;1462-1472.
29. 2B ligands, J. Med. Chem., 45 (2002) 3271-3279.
30. V. Nair, S.G. Richardson, Modification of nucleic acid bases via radical intermediates: synthesis of dihalogenated purine nucleosides, Synthesis (1982) 670-672.
31. 3 adenosine receptor agonists. J. Med. Chem. 41:1998;3174-3185.
32. Volpini R., Camaioni E., Costanzi S., Vittori S., Klotz K.-N., Cristalli G. Synthesis of di- and tri-substituted adenosine derivatives and their affinity at human adenosine receptor subtypes. Nucleosides Nucleotides. 18:1999;2511-2520.
33. Klotz K.-N., Hessling J., Hegler J., Owman B., Kull B., Fredholm B.B., Lohse M.J. Comparative pharmacology of human adenosine subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;1-9.
34. 3 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;103-108.
35. 3 adenosine receptor. Bioorg. Med. Chem. Lett. 11:2001;1931-1934.
36. Lambertucci C., Costanzi S., Vittori S., Volpini R., Cristalli G. Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine. Nucleosides Nucleotides Nucleic Acids. 20:2001;1153-1157.
37. Bruns R.F. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can. J. Physiol. Pharmacol. 58:1980;673-691.
38. Stolarski R., Dudycz L., Shugar D. NMR studies in the syn-anti dynamic equilibrium in purine nucleosides and nucleotides. Eur. J. Biochem. 108:1980;111-121.
39. 1H NMR study of the syn-anti dynamic equilibrium in adenine nucleosides and nucleotides with the aid of some synthetic model analogues with fixed conformations. Z. Naturforsch., Teil. C. 34C:1979;359-373.
40. 3 receptor can explain their different biological behavior, J. Molec. Graphics Model., 21 (2003) 253-262.
41. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: AG protein-coupled receptor. Science. 289:2000;739-745.
42. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 28:2000;235-242.
43. van der Wenden E.M., Von Frijtag Drabbe Kunzel J.K., Mathot R.A., Danhof M., IJzerman A.P., Soudijn W. Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J. Med. Chem. 38:1995;4000-4006.